The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).
Kathleen N. Moore
Consultant or Advisory Role - AstraZeneca
Paul DiSilvestro
Research Funding - AstraZeneca
Elizabeth S. Lowe
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Sally Garnett
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Eric Pujade-Lauraine
No relevant relationships to disclose